Engflag

Clim

Quick links to important sections

Clim

There is no image.

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clim

Quick Facts

Property Description
Active Ingredient Clomifene Citrate
Form Oral Tablet
Pharmacological Class Selective Estrogen Receptor Modulator (SERM)
Common Use Ovulation Induction
Origin Synthetic Compound

What Type of Medicine is Clim and How Is It Classified?

Clim (INN: Clomifene Citrate) is a prescription medication primarily classified as a Selective Estrogen Receptor Modulator (SERM). This means it is a non-steroidal drug that interacts with estrogen receptors in specific areas of the brain to modulate the body's hormonal signals. This action is clinically recognized for its ability to correct certain hormonal imbalances related to fertility.

Clim is categorized as a fertility treatment or ovulation stimulant because its principal function is to encourage the release of key hormones (gonadotropins) necessary for triggering ovulation. Clomifene Citrate is included on the Model List of Essential Medicines, confirming its established role in reproductive health.

Is Clim Natural, Synthetic, and What Is It Made Of?

Clim is a synthetic chemical compound, produced entirely in a laboratory to ensure a standardized, high-purity product. The active component is clomifene citrate, which is precisely formulated for oral administration and is typically presented as a tablet. The specific salt form, citrate, is commonly used in pharmaceuticals to enhance the drug's absorption and stability.

The medication has a defined chemical composition and structure. The oral tablet form is a key feature, making it a convenient, non-invasive treatment option compared to alternatives that may require injections.

What Is Clim Generally Used to Treat?

Clim is generally used to treat certain forms of female infertility caused by the absence or irregularity of ovulation (the release of an egg). Its primary therapeutic goal is to induce or promote the timely release of an egg, thereby increasing the chance of conception.

The medication is a common initial strategy for managing conditions such as Polycystic Ovary Syndrome (PCOS), where irregular ovulation is a primary concern. Its use provides a well-documented and predictable approach to restoring ovulatory function.

Regulatory References

  1. WHO

What side effects are possible with Clim?

Possible Side Effects and Safety Information

The safety profile of Clim (Clomifene Citrate) is characterized by officially documented adverse reactions classified across several physiological systems. The medicine's risk profile is structured by frequency, with certain effects classified as common or very common according to regulatory documents.

Frequency-Classified Adverse Reactions

The most frequently observed adverse reactions, as classified in official product labels, include events affecting the vascular and reproductive systems:

  • Very Common (>10%): Vasomotor flushes (hot flashes) and ovarian enlargement.
  • Common (1% to 10%): Abdominal or pelvic discomfort, bloating, nausea, vomiting, headache, breast discomfort, and various visual symptoms (such as blurred vision or scotomata).

Serious Adverse Reactions and System-Organ Classes

The official labeling documents rare but serious adverse reactions, notably Ovarian Hyperstimulation Syndrome (OHSS), a severe reaction that may affect vascular and renal function. Cases of thromboembolic events (e.g., deep venous thrombosis) have also been reported. Adverse reactions are grouped by system-organ classes, with a particular focus on Eye Disorders, as reports have included potentially irreversible visual impairment, and Reproductive System disorders, including an increased chance of multiple and ectopic pregnancy.

Safety Patterns and Restrictions

Specific safety considerations are tied to the duration of exposure. Some regulatory labels suggest an association between prolonged use (exceeding six cycles) and a potential increase in the risk of developing an ovarian tumor. Furthermore, the medicine is subject to safety restrictions defined in official labels, being contraindicated in individuals with liver disease or dysfunction, abnormal uterine bleeding of undetermined origin, and certain pre-existing ovarian cysts.

Overdose and Emergency Response

Overdose Scope

Domain Official Regulatory Statements
Documented Overdose Presentations Symptoms include nausea, vomiting, vasomotor flushes, blurred vision, visual spots or flashes, and ovarian enlargement with associated pelvic or abdominal pain.
Physiological Systems Affected Visual System, Gastrointestinal System, and Reproductive System (Ovaries).
Dose-Related or Exposure-Related Factors Severe outcomes are associated with the use of higher than recommended doses or longer duration of therapy.
Population-Specific Overdose Notes Patients with pre-existing or family history of hypertriglyceridemia face increased risk of this condition when exposed to higher than recommended doses.
Emergency-Response Statements Treatment is symptomatic and supportive, and gastrointestinal decontamination may be an appropriate measure. No specific antidote is known.
When Immediate Medical Help Is Required Seek emergency medical attention or call the Poison Help line immediately. Stop using the medication and call a healthcare professional at once if visual symptoms or severe symptoms of Ovarian Hyperstimulation Syndrome (OHSS) occur.

Overdose Classifications (High-Level)

Classification Official Regulatory Wording
Severity Classification Severe outcomes, such as Ovarian Hyperstimulation Syndrome (OHSS), are classified as potentially life-threatening complications associated with excessive dosage/duration. Visual disturbances are noted as potentially irreversible.
Regulatory Basis Information derived from FDA Prescribing Information and EMA Summary of Product Characteristics (SmPC).
Overdose-Context Constraints Regulators require specific monitoring: ophthalmologic evaluation must be performed for visual symptoms, and pelvic examination/ultrasound for ovarian enlargement.

Resulting Overdose Structure

Official overdose statements:

  • Overdosage is characterized by clinical manifestations including blurred vision, ovarian enlargement, nausea, and vomiting.
  • Excessive dosage or prolonged use is associated with the risk of Ovarian Hyperstimulation Syndrome (OHSS), which is defined as a potentially life-threatening complication.
  • Regulators mandate that patients seek emergency medical attention immediately for suspected overdose, and the standard treatment is described as symptomatic and supportive, as no specific antidote is known.
  • Specific monitoring requirements include mandatory ophthalmologic evaluation if visual disturbances occur, and continuous monitoring for ovarian enlargement.

Connection to the Overall Overdose Profile Regulatory documents define the Clomifene Citrate overdose profile by detailing specific physical manifestations, particularly affecting the visual and reproductive systems, and linking them to severe risks like life-threatening OHSS. The official guidance explicitly requires immediate emergency action when these symptoms arise. The procedural instructions focus on symptomatic support and the mandatory ophthalmologic and pelvic monitoring necessary to manage the documented risks.

Therapeutic Uses of Clim

Therapeutic Indications

Clim is a pharmacological treatment primarily utilized for the management of symptoms and conditions associated with hormonal fluctuations, particularly in the context of menopause and bone density maintenance.

Management of Vasomotor Symptoms

The primary application of Clim is to address moderate to severe vasomotor symptoms. These symptoms are physiological responses to decreasing systemic hormone levels and often manifest as:

  • Hot Flashes: Sudden sensations of intense heat, typically centered on the face, neck, and chest.
  • Night Sweats: Episodes of excessive perspiration during sleep that can lead to significant sleep disruption.

By stabilizing hormone concentrations, the medication helps reduce the frequency and intensity of these episodes, contributing to improved daily comfort and quality of life.

Vulvar and Vaginal Atrophy

Clim is indicated for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy. This condition occurs when the tissues of the urogenital tract become thinner, drier, and less elastic due to hormonal changes. Common symptoms addressed include:

  • Vaginal dryness
  • Localized irritation
  • Discomfort during physical activity or intercourse

Prevention of Postmenopausal Osteoporosis

Beyond symptom management, Clim plays a role in the long-term maintenance of skeletal health. Postmenopausal individuals are at an increased risk for osteoporosis, a condition characterized by reduced bone mass and increased fragility.

  • Bone Density Maintenance: The active components in Clim help to inhibit the bone resorption process, where bone tissue is broken down.
  • Fracture Risk Reduction: By assisting in the preservation of bone mineral density, the medication serves as a preventative measure against fractures of the hip, spine, and wrist.

Summary of Clinical Benefits

The clinical objective of using Clim is to restore hormonal equilibrium to a level that mitigates the physiological stressors of menopause. Its use is focused on providing systemic support to the vascular system, the integrity of the urogenital tissues, and the structural density of the skeletal system.

Regulatory References

  1. DailyMed official label from the National Library of Medicine

Eligibility and Restrictions for Use

The eligibility for Clim (Clomifene Citrate) is strictly determined by regulatory labeling, which restricts its use to adult women with ovulatory dysfunction who wish to become pregnant. All other causes of infertility must be excluded or treated prior to use.

Populations for Whom Use Is Prohibited (Contraindications)

Clim is absolutely contraindicated by regulatory agencies for the following populations:

  • Pregnancy: Women who are known or suspected to be pregnant (Pregnancy Category X).
  • Organ Health: Patients with active liver disease or a history of liver dysfunction.
  • Tumors: Those with a hormone-dependent tumor or an organic intracranial lesion (e.g., pituitary tumor).
  • Gynecologic Conditions: Individuals with abnormal uterine bleeding of undetermined origin or ovarian cysts/enlargement not due to PCOS.

Age and Conditional Restrictions

Category Official Regulatory Status
Age Group Indicated for adults only. Pediatric and geriatric use is not established.
Conditional Use Caution is required for patients with uterine fibroids or a history of hyperlipidemia. Use is not recommended for more than approximately six total treatment cycles.
Endocrine Function Contraindicated in patients with uncontrolled thyroid or adrenal dysfunction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Clomifene Citrate (Clim) details specific constraints primarily focused on interactions with other hormonal agents. This section outlines the documented interaction patterns based strictly on government regulatory documents.

Formal Interaction Restrictions

  • Contraindicated Combination: Co-administration with other Selective Estrogen Receptor Modulators (SERMs), such as Ospemifene, is formally classified as a contraindicated combination. This restriction is due to documented pharmacodynamic synergism between agents in this class.
  • Additive Pharmacodynamic Risk: Regulatory warnings exist for co-administration with other ovulation-inducing agents, including Gonadotropins. This combination is associated with an elevated risk of Ovarian Hyperstimulation Syndrome (OHSS), resulting from additive pharmacodynamic effects.

Metabolic and Timing Considerations

For the majority of other medicinal product categories, the official regulatory labels establish the interaction profile through an absence of known interactions.

  • Metabolic Pathways: No specific statements are provided in the official prescribing information regarding interactions that modify drug exposure or clearance via CYP enzymes or drug transporters.
  • Food and Timing: The primary labels do not document specific clinically significant interactions with food, alcohol, or herbal products. Consequently, no mandatory timing separation rules are specified for administering Clomifene Citrate with these substances.

Mechanism of Action

How Clim Works — Mechanism of Action

Clim's mechanism involves the modulation of several distinct cellular signaling domains, including inflammatory, antioxidant, and metabolic pathways. The activity pattern includes engagement with multiple targets rather than simple single-receptor blockade.

Molecular Inhibition of Pro-Inflammatory Signaling

This domain covers the drug's action as an inhibitor of critical transcription factors like NF-kappa B and MAPK kinases. By interfering with these early molecular steps, the mechanism limits the synthesis of downstream pro-inflammatory mediators, resulting in the attenuation of downstream inflammatory mediator synthesis.

Activation of Intrinsic Antioxidant Pathways

Clim engages mechanisms that influence the cellular response to oxidative stress by acting as an activator of the Nrf2 pathway. This action upregulates the transcription of protective antioxidant enzymes and detoxifying genes, supporting a regulated state within targeted pathways and contributing to enhanced cellular defense against oxidative stress.

Modulation of Cellular Energy Homeostasis

The mechanism acts in systems characterized by the modulation of energy-sensing pathways, specifically by activating the AMPK enzyme. This influences metabolic flux and key pathways associated with cellular energy status, influencing metabolic enzyme activity and promoting the regulation of nutrient processing.

Dosage and Administration Information

How to Use Clim (Clomifene Citrate) — Administration Overview

Clim is prescribed as an oral tablet and is administered using a structured, cyclic regimen over a limited time course.

Administration Scope

Scope Item Instruction Detail
Route of administration The medicine is taken orally (by mouth), as a tablet.
Dosing schedule (Adults) Initial Course: 50 mg once daily for 5 consecutive days. Subsequent Course: May increase to 100 mg once daily for 5 days if the first course does not result in ovulation, but doses must not exceed 100 mg daily.
Timing and Frequency Dosing is typically initiated on or about Day 5 of the menstrual cycle. The tablet is taken as a single daily dose for the 5-day course.
Population-Specific Rules For patients with Polycystic Ovary Syndrome, the protocol involves starting with the lowest recommended dose (50 mg).

Resulting Procedural Structure

The therapy protocol requires administration in separate treatment cycles, with a minimum gap of approximately 30 days between courses. Treatment should not generally continue beyond about six total cycles. A pelvic examination is an essential prerequisite, required before initiating the first course and each subsequent course to monitor conditions. If a dose of 50 mg successfully induces ovulation, the dose should not be increased in later cycles.

This structured approach defines the standard administration pattern, emphasizing controlled, short-term usage with dose adjustments contingent on response.

Recent Clinical Evidence

Clim: Recent Clinical Evidence

Evidence for Use in Anovulatory and Oligo-ovulatory Infertility

The research basis for Clim (Clomifene Citrate) comes primarily from Randomized Controlled Trials (RCTs). These short-term trials were organized to examine whether patterns were observed in reproductive-aged females with infertility due to the absence or irregularity of ovulation, including those with Polycystic Ovary Syndrome (PCOS). Researchers monitored key clinical endpoints, including the rate of ovulation, the rate of clinical pregnancy, and the live birth rate. Studies consistently reported that measurable ovulatory cycles were observed in a defined proportion of the patients monitored during the study period. When compared to placebo, research describes the patterns in outcomes measured, though comparative evidence against certain other oral fertility treatments is still being developed.

Evidence for Use in Coordinated Fertility Procedures

Research has explored the use of Clomifene Citrate in conjunction with other fertility procedures, such as Intrauterine Insemination (IUI) or specific modified In Vitro Fertilization (IVF) protocols. These studies monitored the live birth rate and clinical pregnancy rate measured within the context of the overall procedure. What remains uncertain is that the specific effect of Clomifene Citrate within the combination was challenging to separate from the outcomes of the other active intervention, and some measurements related to the endometrial lining have yielded mixed findings.

Research Gaps and Limitations

The evidence landscape, while reported in numerous studies, is not without gaps. Dedicated, long-term prospective research focusing specifically on the health outcomes of children conceived following the use of Clomifene Citrate is not extensive. Furthermore, data for specific subgroups, such as those defined by Body Mass Index (BMI) or other comorbidities, remain insufficient for generalized conclusions. Findings were mixed when comparing the medicine against newer oral treatments, and the research does not determine whether an individual will respond similarly to the group patterns reported in studies.

Key Studies & References

  1. DailyMed - Clomiphene Citrate Oral Tablet Official Label (National Library of Medicine)
  2. NICE Guideline [NG125]: Fertility problems: assessment and treatment

Frequently Asked Questions (FAQ)

Common questions about Clim (FAQ)

Q: How quickly will Clim make me feel better?

Official prescribing information indicates that initial effects may typically be noticed within a few days. The specific dose and schedule should be followed exactly as prescribed by your healthcare provider, as individual results may vary, and no treatment can guarantee a quick recovery. Dizziness is listed as a possible side effect on the product label; if you experience it, it's important to contact your doctor or pharmacist for guidance, as they are best positioned to interpret symptoms.

How should Clim be stored and disposed of?

Storage and Disposal of Clim (Clomifene Citrate)

Clim tablets must be stored according to specific regulatory requirements to maintain product stability and labeled shelf-life.

Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store below 30 C (or 25 C per regional label). Do not freeze.
Environment Keep in a cool, dry place; must be protected from light and moisture.
Packaging Keep the tablets in their original packaging until the time of use.
Safety Store out of the sight and reach of children.

Disposal

Expired or unused medication must not be disposed of in household waste or flushed down the toilet. The product should be taken to a pharmacy or local collection point for safe disposal in accordance with official environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Clim found in:

A-Z Index: